Skip to main content
InnoCare Pharma Limited logo

InnoCare Pharma Limited — Investor Relations & Filings

Ticker · 9969 ISIN · KYG4783B1032 LEI · 3003001NYJPPWIEOJT79 HKEX Manufacturing
Open in API
Filings indexed 428 across all filing types
Latest filing 2025-12-11 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9969

About InnoCare Pharma Limited

http://www.innocarepharma.com

InnoCare Pharma Limited is a commercial stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative drugs. The company focuses primarily on creating potentially best-in-class and first-in-class therapies for the treatment of cancer (oncology) and autoimmune diseases. InnoCare researches, develops, and commercializes its pipeline with the goal of delivering safe and effective treatments to patients globally.

Recent filings

Filing Released Lang Actions
INSIDE INFORMATION ANNOUNCEMENT - APPROVAL OF ZURLETRECTINIB FOR THE TREATMENT OF ADULT AND ADOLESCENT PATIENTS WITH SOLID TUMORS HARBORING NTRK GENE FUSIONS IN CHINA
Regulatory Filings Classification · 1% confidence The document is an 'Inside Information Announcement' issued by InnoCare Pharma Limited regarding the NMPA approval of a new drug (zurletrectinib). It does not fit into specific categories like financial reports, dividend notices, or director dealings. As it is a regulatory announcement regarding company operations and product development that does not fall into the other specialized categories, it is classified as a general Regulatory Filing (RNS).
2025-12-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report movements in their securities, share capital, and treasury shares on a monthly basis. As it is a recurring regulatory filing regarding share capital and securities movements that does not fit into specific categories like 'Share Issue' (which usually refers to a specific event) or 'Director's Dealing', it is best classified as a Regulatory Filing (RNS).
2025-12-04 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 1% confidence The document is a formal notification listing the current members of the Board of Directors and their respective roles and committee memberships for InnoCare Pharma Limited. This type of disclosure is a standard corporate governance update regarding board composition, which falls under the category of general regulatory filings or governance-related announcements. Since it does not announce a change in management (MANG) but rather provides the current structure, and does not fit other specific categories, it is classified as a general regulatory filing.
2025-11-13 English
(1) 2025 QUARTERLY REPORT FOR THE THIRD QUARTER AND (2) CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE
Interim / Quarterly Report Classification · 1% confidence The document is a '2025 Third Quarterly Report' for InnoCare Pharma Limited. It contains comprehensive financial statements, key accounting data, management performance reviews, and non-recurring profit/loss items for the third quarter of 2025. Although it also mentions a change in the composition of the nomination committee, the primary purpose and the bulk of the content constitute a formal quarterly financial report. It is not an announcement of a report (RPA) because it contains the actual financial data and tables within the text itself. Q3 2025
2025-11-13 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 1% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-11-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
Regulatory Filings Classification · 1% confidence The document is the FF301 Monthly Return for Equity Issuers and Hong Kong Depositary Receipts under Chapter 19B of the HKEX Listing Rules, detailing movements in authorised, issued, and treasury shares, plus share repurchases. It is a routine periodic regulatory return to the Hong Kong Exchange rather than an annual or interim report, earnings release, proxy, M&A, or other specific transaction notice. Therefore it falls under the general “Regulatory Filings” fallback category.
2025-11-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.